- Home
- CHPT vs CCCC Comparison
CHPT vs CCCC Comparison
Compare CHPT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | CCCC |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.1M | 185.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHPT | CCCC |
|---|---|---|
| Price | $4.82 | $2.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $9.67 | ★ $12.20 |
| AVG Volume (30 Days) | 436.4K | ★ 2.0M |
| Earning Date | 03-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | $35,947,000.00 |
| Revenue This Year | $5.62 | N/A |
| Revenue Next Year | $12.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $0.52 | $1.09 |
| 52 Week High | $12.62 | $3.82 |
Technical Indicators
Market Signals| Indicator | CHPT | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 35.89 | 55.61 |
| Support Level | $0.61 | $2.26 |
| Resistance Level | $6.73 | $2.85 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 31.03 | 90.43 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.